Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Open-Label Study to Assess Pharmacokinetic and Pharmacodynamic Parameters Following Dosing with an Anti-Tumor Necrosis Factor Monoclonal Antibody (Humira, adalimumab) Enema in Patients with Active Ulcerative Colitis

Next Previous
X
Search
Trial Profile

Phase 1 Open-Label Study to Assess Pharmacokinetic and Pharmacodynamic Parameters Following Dosing with an Anti-Tumor Necrosis Factor Monoclonal Antibody (Humira, adalimumab) Enema in Patients with Active Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Adalimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Biora Therapeutics

    • Most Recent Events

    • 26 Oct 2022 Results investigating the effects of topical dosing of adalimumab in active ulcerative colitis patients, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
    • 02 Feb 2022 Actual date of last participant enrolled is 28/06/2021 according to Australian New Zealand Clinical Trials Registry record.
    • 02 Feb 2022 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top